Natco Pharma's Marketing Partner Gets USFDA Nod For Cancer Treatment Drug

Drug major Natco Pharma on Friday said its marketing partner Breckenridge Pharmaceutical has received final approval from the US health regulator for Pomalidomide Capsules, treatment of patients suffering from multiple myeloma cancer.

"Breckenridge Pharmaceutical Inc. has received final approval for its abbreviated new drug application (ANDA) for Pomalidomide Capsules from the US Food and Drug Administration (USFDA)," Natco Pharma said in a regulatory filing.

In addition, Natco and Breckenridge have settled the patent litigation with Celgene (now part of Bristol-Myers Squibb) in the US district court for this product, the company added.

The company, however, did not share details of the settlement.

Celgene sells Pomalidomide Capsules under Brand name Pomalyst in the USA market which is indicated for the treatment of patients suffering from multiple myeloma cancer.

Natco Pharma said as per industry sales data, Pomalyst had annual sales of USD 957 million during the twelve months ending September 2020.

Shares of Natco Pharma were trading 0.50 per cent higher at Rs 910.40 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor